Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen K Field

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Expert Opinion on Investigational Drugs|May 2, 2008
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthmaStephen K Field
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|November 16, 2011
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of ExacerbationsStephen K Field
Therapeutic Advances in Chronic Disease|July 3, 2015
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Stephen K Field
Chest|June 17, 2006
Lung disease due to the more common nontuberculous mycobacteriaStephen K Field, Robert L Cowie
Chest|October 14, 2003
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimineStephen K Field, Robert L Cowie
Drug Design, Development and Therapy|August 7, 2010
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPDMark A Giembycz, Stephen K Field
Drugs|December 8, 2022
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of TuberculosisBrett D Edwards, Stephen K Field
Chest|August 11, 2004
Mycobacterium avium complex pulmonary disease in patients without HIV infectionStephen K Field, Dina Fisher, Robert L Cowie
Canadian Respiratory Journal|September 22, 2007
Asthma symptoms do not predict spirometryRobert L Cowie, Margot F Underwood, Stephen K Field
Canadian Respiratory Journal|January 28, 2017
Is Universal Screening Necessary? Incidence of Tuberculosis among Tibetan Refugees Arriving in Calgary, AlbertaRachel Lim, Julie Jarand, Stephen K Field, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|May 2, 2008
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthmaStephen K Field
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|November 16, 2011
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of ExacerbationsStephen K Field
Therapeutic Advances in Chronic Disease|July 3, 2015
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Stephen K Field
Chest|June 17, 2006
Lung disease due to the more common nontuberculous mycobacteriaStephen K Field, Robert L Cowie
Chest|October 14, 2003
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimineStephen K Field, Robert L Cowie
Drug Design, Development and Therapy|August 7, 2010
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPDMark A Giembycz, Stephen K Field
Drugs|December 8, 2022
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of TuberculosisBrett D Edwards, Stephen K Field
Chest|August 11, 2004
Mycobacterium avium complex pulmonary disease in patients without HIV infectionStephen K Field, Dina Fisher, Robert L Cowie
Canadian Respiratory Journal|September 22, 2007
Asthma symptoms do not predict spirometryRobert L Cowie, Margot F Underwood, Stephen K Field
Canadian Respiratory Journal|January 28, 2017
Is Universal Screening Necessary? Incidence of Tuberculosis among Tibetan Refugees Arriving in Calgary, AlbertaRachel Lim, Julie Jarand, Stephen K Field, et al.
Pageof 5